Cytek BiosciencesCTKB -1.30%71 Debt-to-EBITDA is -0.48 as of Mar. 2026. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.83 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Cytek Biosciences ranks worse than 213675% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cytek Biosciences's Debt-to-EBITDA or its related term are showing as below:
CTKB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.21 Med: -1.37 Max: 1.91
Current: -1.17
During the past 7 years, the highest Debt-to-EBITDA Ratio of Cytek Biosciences was 1.91. The lowest was -3.21. And the median was -1.37.
CTKB's Debt-to-EBITDA is ranked worse than 100% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs CTKB: -1.17
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cytek Biosciences Debt-to-EBITDA Related Terms
Cytek Biosciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTKB vs CERS, NPCE, CLPT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Cytek Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Cytek Biosciences (CTKB) has a Debt-to-EBITDA of -0.48 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cytek Biosciences. According to the industry distribution chart, Cytek Biosciences ranks #999999 out of 468 companies in the Medical Devices & Instruments industry.
Is Cytek Biosciences' Debt-to-EBITDA too high?
Cytek Biosciences' current Debt-to-EBITDA is -0.48. Based on the distribution chart, Cytek Biosciences ranks #999999 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Debt-to-EBITDA compare to CERS and NPCE?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #999999 out of 468 companies for Debt-to-EBITDA. This places Cytek Biosciences in the lower half of its industry. The industry median Debt-to-EBITDA is 1.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cytek Biosciences. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current Debt-to-EBITDA is -0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.83, compared to a current price of $4.57 — trading 21.6% below its estimated fair value. The current Debt-to-EBITDA is -0.48. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Debt-to-EBITDA is -0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.57 is trading 21.6% below its estimated GF Value™ of $5.83.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
Debt-to-EBITDA: -0.48
GF Value™: $5.83 vs. price of $4.57 (21.6% below fair value)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
